Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Life Sci ; 239: 116961, 2019 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-31654745

RESUMEN

Neuropathic pain (NP) is a difficult condition to treat because of the modest efficacy of available drugs. New treatments are required. In the study we aimed to investigate the effects of the essential oil from Lippia grata alone or complexed in ß-cyclodextrin (LG or LG-ßCD) on persistent inflammatory and neuropathic pain in a mouse model. We also investigated Ca2+ currents in rat dorsal root ganglion (DRG) neurons. Male Swiss mice were treated with LG or LG/ß-CD (24 mg/kg, i.g.) and their effect was evaluated using an acute inflammatory pleurisy model and nociception triggered by intraplantar injection of an agonist of the TRPs channels. We also tested their effect in chronic pain models: injection of Freund's Complete Adjuvant and partial sciatic nerve ligation (PSNL). In the pleurisy model, LG reduced the number of leukocytes and the levels of TNF-α and IL-1ß. It also inhibited cinnamaldehyde and menthol-induced nociceptive behavior. The pain threshold in mechanical and thermal hyperalgesia was increased and paw edema was decreased in models of inflammatory and neuropathic pain. PSNL increased inflammatory protein contents and LG and LG-ßCD restored the protein contents of TNF-α, NF-κB, and PKA, but not IL-1ß and IL-10. LG inhibited voltage gated Ca2+ channels from DRG neurons. Our results suggested that LG or LG-ßCD produce anti-hyperalgesic effect in chronic pain models through reductions in TNF-α levels and PKA, and inhibited voltage-gated calcium channels and may be innovative therapeutic agents for the management of NP.


Asunto(s)
Hiperalgesia/tratamiento farmacológico , Lippia/metabolismo , beta-Ciclodextrinas/farmacología , Animales , Dolor Crónico/tratamiento farmacológico , Modelos Animales de Enfermedad , Ganglios Espinales/efectos de los fármacos , Hiperalgesia/metabolismo , Masculino , Ratones , Neuralgia/tratamiento farmacológico , Nocicepción/efectos de los fármacos , Aceites Volátiles/farmacología , Dolor/tratamiento farmacológico , Dolor/metabolismo , Dimensión del Dolor/efectos de los fármacos , Umbral del Dolor/efectos de los fármacos , Extractos Vegetales/farmacología , Ratas , Ratas Wistar , beta-Ciclodextrinas/metabolismo
2.
Neuroscience ; 358: 158-169, 2017 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-28673718

RESUMEN

Chronic musculoskeletal pain is one of the main symptoms found in Fibromyalgia with unclear etiology and limited pharmacological treatment. The aim of this study was to complex LIM in ß-cyclodextrin (LIM-ßCD) and then evaluate its antihyperalgesic effect in an animal model of chronic musculoskeletal pain. Differential scanning calorimetry and scanning electron microscopy was used for the characterization of the inclusion complex. Male Swiss mice were used for experimental procedures where mechanical hyperalgesia, thermal hyperalgesia, muscular strength, Fos immunofluorescence was studied after induction of hyperalgesia. Mechanism of action was also investigated through tail flick test and capsaicin-induced nociception. Endothermic events and morphological changes showed that the slurry complex method was the best method for the complexation. After induction of hyperalgesia, the oral administration of LIM-ßCD (50mg/kg) significantly increased the paw withdrawal threshold compared to uncomplexed limonene. Fos immunofluorescence showed that both compounds significantly decreased the number of Fos-positive cells in the dorsal horn. In nociceptive tests, FLU was able to reverse the antinociceptive effect of LIM-ßCD. After intraplantar administration of capsaicin, LIM was able to significantly decrease time to lick. LIM-ßCD has antihyperalgesic action superior to its uncomplexed form, with possible action in the dorsal horn of the spinal cord. These results suggest the possible applicability of LIM, uncomplexed or complexed with ßCD, in conditions such as FM and neuropathic pain, for which there are currently only limited pharmacological options.


Asunto(s)
Analgésicos/uso terapéutico , Ciclohexenos/uso terapéutico , Dolor Musculoesquelético/tratamiento farmacológico , Dolor Musculoesquelético/patología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Médula Espinal/efectos de los fármacos , Terpenos/uso terapéutico , beta-Ciclodextrinas/uso terapéutico , Animales , Capsaicina/toxicidad , Modelos Animales de Enfermedad , Combinación de Medicamentos , Interacciones Farmacológicas , GABAérgicos/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Limoneno , Masculino , Ratones , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Dolor Musculoesquelético/inducido químicamente , Nocicepción/efectos de los fármacos , Dimensión del Dolor/efectos de los fármacos , Dimensión del Dolor/métodos , Umbral del Dolor/efectos de los fármacos , Médula Espinal/metabolismo , Estadísticas no Paramétricas
3.
Biomed Pharmacother ; 93: 754-762, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28704800

RESUMEN

Hecogenin acetate (HA) is a steroidal sapogenin-acetylated with pharmacological properties which have already been described in the literature such as, anti-inflammatory, anti-hyperalgesic and antinociceptive, but it has low solubility in aqueous media. Therefore, in an attempt to overcome this, we set out to create inclusion complexes between HA and b-cyclodextrin (b-CD) and evaluate the antinociceptive effects in the orofacial nociception in mice. The complexes were prepared using different methods in the molar ratios 1:1 and 1:2 and characterized physicochemically. The results of the physicochemical characterization elucidated inclusion complexes formation between b-CD and HA by freeze drying method in the molar ratio 1:2, which obtained a complexation efficiency of 92% and produced superior analgesic effect in animal models for orofacial pain at a lower dose when compared to HA alone.


Asunto(s)
Analgésicos/química , Analgésicos/farmacología , Dolor Facial/tratamiento farmacológico , Compuestos de Espiro/química , Compuestos de Espiro/farmacología , Esteroides/química , Esteroides/farmacología , beta-Ciclodextrinas/química , beta-Ciclodextrinas/farmacología , Animales , Composición de Medicamentos/métodos , Liofilización/métodos , Masculino , Ratones , Modelos Animales , Solubilidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA